A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool

Neuro-Oncology

Volumn 16, Issue 4, 2014, Pages 520-527

  Manterola, Lorea ^a   Guruceaga, Elizabeth ^b   Pérez Larraya, Jaime Gállego ^c   González Huarriz, Marisol ^c   Jauregui, Patricia ^c   Tejada, Sonia ^c   Diez Valle, Ricardo ^c   Segura, Victor ^b   Samprón, Nicolás ^a   Barrena, Cristina ^a   Ruiz, Irune ^a   Agirre, Amaia ^d,e   Ayuso, Ángel ^a   Rodríguez, Javier ^c   González, Álvaro ^c   Xipell, Enric ^c   Matheu, Ander ^a   López De Munain, Adolfo ^a   Tuñón, Teresa ^g   Zazpe, Idoya ^g   García Foncillas, Jesús ^f   Paris, Sophie ^h   Delattre, Jean Yves ^h   Alonso, Marta M ^c   more..

^a HOSPITAL DONOSTIA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e Hospital de Madrid   (Spain)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^g Universidad Pública de Navarra   (Spain)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Biomarkers; Diagnosis; Exosomes; GBM; sncRNAs

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; SMALL UNTRANSLATED RNA;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EXOSOME; FEMALE; GLIOBLASTOMA; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; VALIDATION STUDY;

BIOMARKERS; DIAGNOSIS; EXOSOMES; GBM; SNCRNAS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; EXOSOMES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896971533     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not218     Document Type: Article

References (48)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Smirniotopoulos JG, Murphy FM, Rushing EJ, et al. Patterns of contrast enhancement in the brain and meninges. Radiographics. 2007;27(2): 525-551.
3. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-10518.
4. Houali K,Wang X, Shimizu Y, et al. Anewdiagnostic marker for secreted Epstein-Barr virus encodedLMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res. 2007;13(17):4993-5000.
5. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883-891.
6. Shao H, ChungJ, Balaj L, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012; 18(12):1835-1840.
7. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569-579.
8. Bergmann C, Strauss L, Wieckowski E, et al. Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck. 2009;31(3):371-380.
9. Kim JW, Wieckowski E, Taylor DD, et al. Fas ligand-positivemembranous vesicles isolated fromsera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010-1020.
10. Andre F, Schartz NE, Chaput N, et al. Tumor-derived exosomes: a new sourceof tumor rejectionantigens. Vaccine.2002;20(Suppl4):A28-A31.
11. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470-1476.
12. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.
13. Rabinowits G, Gercel-Taylor C, Day JM, et al. Exosomal microRNA: a diagnosticmarker for lung cancer. Clin LungCancer. 2009;10(1):42-46.
14. Taylor DD, Zacharias W,Gercel-Taylor C.Exosomeisolationfor proteomic analyses and RNA profiling. Methods Mol Biol. 2011;728:235-246.
15. Calin GA, Ferracin M, Cimmino A, et al.AmicroRNAsignature associated with prognosisandprogression in chroniclymphocytic leukemia.NEngl J Med. 2005;353(17):1793-1801.
16. Hermansen SK, Dahlrot RH, Nielsen BS, et al. MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol. 2013;111(1):71-81.
17. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10(5):619-624.
18. Camacho L, Guerrero P,Marchetti D.MicroRNAand protein profiling of brain metastasis competent cell-derived exosomes. PLoS One. 2013;8(9): e73790.
19. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13-21.
20. Gentleman R. Reproducible research: a bioinformatics case study. Stat Appl Genet Mol Biol. 2005;4: article 2.
21. Schmittgen TD. Part B - microRNAs: microRNA methods. Methods. 2008;44(1):1-2.
22. Schmittgen TD, Lee EJ, Jiang J, et al. Real-time PCR quantification of precursor and mature microRNA. Methods. 2008;44(1):31-38.
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3: article 3.
24. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100(16):9440-9445.
25. Mestdagh P, Van Vlierberghe P, DeWeer A, et al. A novel and universal method for microRNART-qPCR data normalization.GenomeBiol. 2009; 10(6):R64.
26. Hastie TTR, Friedman J. The Elements of Statistical Learning: Prediction, Inference and Data Mining. New York: Springer; 2001.
27. Sing T, Sander O, Beerenwinkel N, et al. ROCR: visualizing classifier performance in R. Bioinformatics. 2005;21(20):3940-3941.
28. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73(10): 1907-1920.
29. Roth P, Wischhusen J, Happold C, et al.AspecificmiRNAsignature inthe peripheral blood of glioblastoma patients. J Neurochem. 2011;118(3): 449-457.
30. Teplyuk NM,Mollenhauer B, Gabriely G, et al. MicroRNAsin cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 2012;14(6):689-700.
31. Yang C,Wang C, Chen X, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013;132(1):116-127.
32. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-269.
33. Graner MW, Alzate O, Dechkovskaia AM, et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009;23(5):1541-1557.
34. Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011;2:180.
35. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005;334(4):1351-1358.
36. Rao SA, Santosh V, Somasundaram K. Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol. 2010;23(10):1404-1417.
37. Valadkhan S. Role of the snRNAs in spliceosomal active site. RNA Biol. 2010;7(3):345-353.
38. White RJ, Trouche D, Martin K, et al. Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature. 1996;382(6586): 88-90.
39. Cabarcas S,Watabe K, SchrammL. Inhibition ofU6snRNA transcription by PTEN. J Biol Sci. 2010;10(3):114-125.
40. Marshall L, White RJ. Non-coding RNA production by RNA polymerase III is implicated in cancer. Nat Rev Cancer. 2008;8(12):911-914.
41. Appaiah HN, Goswami CP, Mina LA, et al. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res. 2011;13(5):R86.
42. Baraniskin A, Nopel-Dunnebacke S, Ahrens M, et al. CirculatingU2small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer. 2013;132(2):E48-E57.
43. Gui J, Tian Y,Wen X, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci. 2011;120(5):183-193.
44. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAsinstageIIcolon cancer.Cancer Res.2008;68(15):6416-6424.
45. Bronisz A, Godlewski J,Wallace JA, et al. Reprogrammingof the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 2011;14(2):159-167.
46. Su Y, Ni Z, Wang G, et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol. 2012;13(4):468-475.
47. Tatarano S, Chiyomaru T, Kawakami K, et al.Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines. Int J Oncol. 2012;40(4):951-959.
48. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res. 2012;5(3):492-497.